B. Arthurs, Kathy Wunderle, M. Hsu, Suil Kim
2017.3.20Respiratory Medicine Case Reports
tlooto Summary
A case of invasive pulmonary aspergillosis is reported in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia, and it is hypothesize that the drug promoted this infection by suppressing innate immune responses against Aspergillus.
Abstract
We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia. We hypothesize that ibrutinib promoted this infection by suppressing innate immune responses against Aspergillus. Clinicians should be aware of potential Aspergillus infections in patients treated with this drug.
Citation format
ARTHURS, B., et al. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respiratory Medicine Case Reports, 2017, 21: 27–29.